News
Stocktwits on MSN53m
Carlsmed Stock Down 6% Since IPO But Goldman Bullish And Predicts 35% Upside Potential — Retail Traders Stay Bearish
Goldman Sachs has started coverage of Carlsmed with a ‘Buy’ rating and a $19 price target, suggesting about 35% upside from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback